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Abstract
Aim In recent years, the clinical availability of scanners for integrated positron emission tomography (PET) and magnetic
resonance imaging (MRI) has enabled the practical potential of multimodal, combined metabolic-receptor, anatomical, and
functional imaging to be explored. The present systematic review and meta-analysis summarize the diagnostic information
provided by PET/MRI in patients with prostate cancer (PCa).
Materials and methods A literature search was conducted in three different databases. The terms used were “choline” or
“prostate-specific membrane antigen - PSMA” AND “prostate cancer” or “prostate” AND “PET/MRI” or “PET MRI” or
“PET-MRI” or “positron emission tomography/magnetic resonance imaging.” All relevant records identified were combined,
and the full texts were retrieved. Reports were excluded if (1) they did not consider hybrid PET/MRI; or (2) the sample size was <
10 patients; or (3) the raw data were not enough to enable the completion of a 2 × 2 contingency table.
Results Fifty articles were eligible for systematic review, and 23 for meta-analysis. The pooled data concerned 2104 patients.
Initial disease staging was the main indication for PET/MRI in 24 studies. Radiolabeled PSMA was the tracer most frequently
used. In primary tumors, the pooled sensitivity for the patient-based analysis was 94.9%. At restaging, the pooled detection rate
was 80.9% and was higher for radiolabeled PSMA than for choline (81.8% and 77.3%, respectively).
Conclusions PET/MRI proved highly sensitive in detecting primary PCa, with a high detection rate for recurrent disease,
particularly when radiolabeled PSMA was used.
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Introduction
The availability of tracers other than 18f-fluorodeoxyglucose
(FDG) suggests new opportunities for the diagnosis and
management of prostate cancer (PCa). The use of different
radiopharmaceuticals, such as radiolabeled choline, or
radiolabeled ligands of prostate-specific membrane antigen
(PSMA), has a significant impact in various clinical settings,
from initial staging to the detection of a biochemical recur-
rence, enabling personalized treatment planning, and
metastasis-directed therapy (MDT) [1, 2]. Such an approach
relies on the diagnostic performance of the imaging modalities
used to detect the real extent and location of metastases. Many
studies on PCa patients have been conducted using PET/CT
[3–5], but most clinical protocols consider magnetic reso-
nance imaging (MRI) the principal imaging modality for stag-
ing and restaging of patients with PCa.
In recent years, the clinical availability of integrated PET/
MRI scanners has made it possible to explore the practical
potential of multimodal, combined metabolic-receptor, ana-
tomical, and functional imaging. The present systematic re-
view and meta-analysis summarize the diagnostic information
obtained with PET/MRI in PCa patients.
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Materials and methods
Search strategy and study selection
A literature search from 2013 up to 23rd March 2020 was
conducted in the PubMed, Scopus, and Web of Science data-
bases. The terms used were as follows: “choline” or “PSMA”
AND “prostate cancer” or “prostate” AND “PET/MRI” or
“PET MRI” or “PET-MRI” or “positron emission
tomography/magnetic resonance imaging.” The search was
carried out with and without the addition of filters, such as
English language only, type of article (original article, re-
search article), and subjects (humans only). Three reviewers
(L.E., F.Z., and P.A.) conducted the literature search, and two
other reviewers (G.C. and D.C.) independently selected the
studies to consider, excluding duplicate papers. Any discrep-
ancy was solved by a consensus. After combining all the re-
cords identified, the full texts were retrieved and further
assessed by four of the reviewers (F.Z, P.A., G.C., and L.E.).
One reviewer (L.E.) ran a new search across the databases,
checking the references of the studies already selected, to en-
sure their eligibility. Reviews, clinical reports, abstracts of
meetings, and editorials were excluded. The qualitative anal-
ysis excluded reports that did not consider hybrid PET/MRI
scanners or that enrolled a very low number of patients (< 5).
Studies were eligible for inclusion in the meta-analysis if all
the following requirements were met: (i) a sample size of more
than ten patients; and (ii) the article included enough raw data
to enable the completion of a 2 × 2 contingency table (or the
authors made said data available on request).
Data extraction
General details were retrieved for each study considered, such
as generic data (authors, journal name, year of publication,
country, and study design), patients’ characteristics (number
of patients and their mean or median age), disease phase (i.e.,
staging or restaging), type of treatment, mean or median PSA
level at the time of PET, and radiotracer used for PET/MRI. A
quality assessment on the studies was performed using the
Quality Assessment of Diagnostic Accuracy Studies 2
(QUADAS-2) [6]. Data extraction and quality assessment
were done independently by three reviewers (L.E., F.Z.,
G.C.), and differences were solved by discussion.
Statistical methods
The pooled detection rate of PET/MRI, with its sensitivities,
specificities, and 95% confidence intervals (CIs), with both
radiolabeled choline and radiolabeled PSMA, was calculated
using random effects analysis. Heterogeneity was tested using
the χ2 and the I2 tests. The χ2 test provided an estimate of the
between-study variance, and the I2 test measured the
proportion of inconsistency in individual studies that cannot
be explained by chance. The values for heterogeneity (I2) of
25%, 50%, and 75% were considered low, moderate, and
high, respectively [7]. Publication bias was assessed using
Deeks’ funnel plot asymmetry test, and a P value above 0.05
suggested the absence of any publication bias. All statistical
analyses were performed using the Meta-DiSc® version 1.4
(developed by the Clinical Biostatistics Unit at Ramón y Cajal
Hospital, Madrid) and Comprehensive Meta-Analysis (CMA)
software version 3.3.070 (Biostat, Englewood, NJ, USA).
Results
Qualitative results
In total, 50 studies were eligible for qualitative analysis
(Fig. 1, Table 1), 20 of them were prospective, and 30 were
retrospective. Overall, the analysis concerned 2059 patients
who underwent hybrid PET/MRI. Disease staging was the
most common reason for the test (n = 24 studies; totally, 940
patients), followed by restaging (n = 16; totally 844 patients),
and both staging and restaging (n = 10; totally 275 patients).
Radiolabeled PSMA was used in the majority of cases (n = 34
studies). In 25 studies, the main endpoint was the ability of
PET/MRI to detect PCa, be it primary or recurrent disease.
Comparisons were drawn between PET/CT and PET/MRI
performed in the same populations in 7 reports.
Methodological quality
All 50 studies were assessed with the QUADAS-2 tool
(Fig. 2). The risk of bias for patient selection was high inmany
papers [10, 15, 19–21, 23, 24, 31, 37, 40–42, 44, 49–51, 53,
55]. The flow and timing were also high in 17 studies [10, 15,
20–24, 26, 27, 31, 32, 35, 44, 45, 51–53]. The applicability of
the studies was adequate in most cases, but unclear as regards
the reference standard in 18 of them [15, 22–24, 27, 34–37,
41–44, 49, 50, 52, 53, 56].
PET/MRI for initial staging
In the present review, 15 studies dealt with PET/MRI used
only in the staging setting for the purpose of detecting primary
disease [11, 12, 14, 18, 29, 31, 33, 35, 38, 40, 44–47, 54, 57].
Integrated PET/MRI proved to be of greater diagnostic
value in locating PCa than either multiparametric (mp) MRI
[11, 14, 18, 29, 35, 44, 45, 54, 58] or PET imaging alone [14,
18, 44]. 68Ga-PSMA-11 PET/MRI showed high lesion con-
trast and an excellent consistency in lesion detection [20].
Intense 18F-labelled PSMA uptake on PET and mpMRI
changes correlated strongly with the dominant lesion in the
prostate glands of men undergoing imaging before surgery
Eur J Nucl Med Mol Imaging
[31]. These results are consistent with other studies where
PET was used to identify PCa lesions. For instance, Park
et al. [38] reported that PCa was detected by 68Ga-PSMA-11
PET in all of their 33 patients, whereas mpMRI with the PI-
RADS (Prostate Imaging Reporting and Data System)
pinpointed 4 or 5 lesions in 26 patients, but missed tumors
in 3. Similarly, Ferrero et al. [47] found primary tumors
PSMA-negative in only 3 of 60 patients, thus reaching a de-
tection rate of 95%.
The assessment of extracapsular extension, tumor grade,
and Gleason score plays an important part in treatment
decisions, and in distinguishing aggressive from indolent dis-
ease. In one study, extracapsular spread of PCa was detected
better with 68Ga-PSMA-11 PET/MRI than with mpMRI (69
vs. 46%) [54]. In another study, PET and PET/MRI produced
a considerably lower proportion of equivocal results (i.e., PI-
RADS 3) than mpMRI [35].
PET/MRI may have also an important role in detecting
local and distant metastases. From a visual inspection of 60
patients’ imaging results, 68Ga-PSMA-11 PET/MRI revealed
positive lymph nodes in 8 patients, with only one patient sub-
sequently resulting false-positive. Most nodes were located in
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Fig. 1 The PRISMA method for
study selection (*filters, journal
article/humans/last 5 years/
English language; **exclusion of
reviews, no inclusion of PET/
MRI in the title and exclusion of
clinical case)
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the pelvis, but distant nodes were found in the common iliac
chain in 2 patients [35]. 68Ga-PSMA-11 PET/MRI provides
valuable diagnostic information and improves patient selec-
tion for extended pelvic lymph node dissection by comparison
with the currently-used clinical nomograms [38, 40, 47].
The rate of changes to patient management can express the
impact of PET/MRI on the initial staging of PCa patients.
Grubmuller et al. [46] reported that including PET/MRI in
the initial workup of patients with PCa could alter the thera-
peutic strategy in at least 30% of cases.
PET/MRI in cases of biochemical disease recurrence
PET/MRI was used to seek biochemical recurrences of PCa
in a total of 598 patients [8, 26, 32, 34, 39, 42, 51, 52, 56].
Taking the studies concerned together, the recurrent disease
detection rate achieved with PET/MRI ranged between 54.5
[56] and 97% [8] (Table 2). In many cases, the authors also
reported the detection rate by PSA category, which rose
with antigen levels from low (< 0.2 ng/mL) to high (>
10 ng/mL). Hope et al. [26] reported a detection rate of
58–64% for PSA levels <0.5 ng/mL using 68Ga-PSMA-
11 PET/MRI, while it was 100% for PSA > 2.0 ng/mL
[26]. Grubmuller et al. [34] confirmed as much. A number
of authors [26, 28, 34, 51] detected a change in patient man-
agement prompted by PET/MRI findings, in proportions of
cases ranging from 53.2 to 74.6%. Based on the study by
Kranzbuhler et al. [56], including PET/MRI in the diagnos-
tic workup could prompt changes to radiotherapy planning
for 39.4% of patients.
PET/CT vs. PET/MRI
PET/MRI and PET/CT were compared in seven studies
(Table 3; [10, 16, 20, 21, 25, 30, 59] encompassing 278 ex-
aminations, 225 of them using 68Ga-PSMA-11 (81%) and 53
with 11C-choline (19%).
The overall discrepancy in PET-positive findings between
PET/CT and PET/MRI was very low, and agreement between
the two methods was high, in the range of 71 to 95% [20, 30,
60]; this also was applied to the semiquantitative analyses [10,
30].
Five studies demonstrated that PET/MRI was superior to
PET/CT in detecting PCa lesions, both in staging and
restaging [16, 21, 25, 30, 59]. In particular, PET/MRI was
more accurate than PET/CT in detecting local recurrences,
thereby improving the detection rate for lower PSA levels.
All authors [16, 21, 25, 30, 59] found the MRI component
crucial in identifying local recurrences otherwise masked by
the accumulation of the radiopharmaceuticals in the bladder,
especially when 68Ga-PSMA-11 was used.
Regarding the assessment of lymph node involve-
ment, PET/MRI achieved a slightly higher detection rateT
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than PET/CT, probably due to a longer tracer accumu-
lation time, as mentioned in the studies by Freitag et al.
[16] and Lutje et al. [25].
As for identifying bone metastases, Eiber et al. [21] argue
that PET/CT and PET/MRI are comparable for PSA levels <
2 ng/mL, and that PET/CT is more efficient for levels > 2 ng/
mL. Freitag et al. [16] and Souvatzoglou et al. [10] claim
instead that using multiple MRI sequences improves the de-
tection of bone metastases, especially in cases of early bone
marrow involvement.
PET/MRI demands a 79.7% (range, 72.6–86.2%) lower
exposure to radiation than PET/CT [21, 59], but the acquisi-
tion time is much longer (60 vs. 20 min) [21]. This latter
aspect is relative to the inclusion of a mpMRI of the
prostate/prostatic fossa that improve significantly the resolu-
tion of prostate scan.
PET/MRI vs. mpMRI
Some papers compared the PCa detection rate or diagnos-
tic performance of PET/MRI and mpMRI in terms of sen-
sitivity and specificity (Table 1s; [13, 14, 18, 29–33, 35,
38, 45, 51, 52, 61]). PET/MRI achieved a higher primary
tumor detection rate than mpMRI [14, 18, 45]. Judging
from the data reported by de Perrot et al. [13] and
Muehlematter et al. [41], PET/MRI was more sensitive
than mpMRI in identifying primary tumor in the periph-
eral zone of prostate gland, and in revealing extracapsular
extension and seminal vesicle infiltration. On the other
hand, mpMRI provided more information about disease
recurrence in the prostatic fossa [30, 51]. As for the de-
tection of lymph node and distant metastases, PET/MRI
was more sensitive than mpMRI, in both staging [38] and
restaging [32, 51].
Radiolabeled PSMA vs. radiolabeled choline PET/MRI
The most papers included radiolabeled PSMA as radiophar-
maceutical agent. The majority of them were focused on
68Ga-PSMA-11 (n = 32 studies), while 2 were based on
18F-PSMA [31, 33]. Radiolabeled choline PET/MRI was
employed in the staging for 8/16 (50%) [11–14, 17, 29, 43,
53], while radiolabeled PSMA in 16/34 (47%) papers [16, 18,
27, 31, 35–37, 40, 44–49, 54]. Conversely, 5/16 (31%) [9, 21,
39, 42, 51] and 11/34 (32%) articles [8, 23, 25, 26, 28, 30, 32,
34, 52, 56] were focused on the resting phase for radiolabeled
choline and PSMA, respectively.
For the identification of primary lesion, PSMA PET/MRI
enriched a specificity of 88%, according to Hicks et al. [45],
while choline PET/MRI registered a specificity equal to 76%
[13]. Therefore, PSMA is more accurate in detecting primary
PCa lesions, by reducing the rate of falsely positive findings.
In restaging, PSMAPET/MRI showed a detection rate of 64%
for PSA values < 0.5 ng/mL in 150 patients [26], therefore
significantly higher than choline PET/MRI (detection rate of
12.5% in 58 patients for the same values of PSA) [51] (see
Table 2).
However, no comparative data are now available about
radiolabeled PSMA and choline PET/MRI in the same popu-
lation, in each phase of disease (i.e., staging or restaging).
Other aspects explored
Six articles considered the image acquisition protocol [19, 23,
24, 37, 48, 53], four discussed technical aspects [15, 22, 41,
55], and eight focused on the interpretation of images obtained
with PET/MRI [9, 12, 17, 27, 36, 43, 49, 50].
The best time per bed acquisition using PET/MRI for PCa
is longer than 3 min [19, 23] because this can reduce the halo
0% 20% 40% 60% 80% 100%
Patient selection
Index test
Reference standard
Flow and timing
low high unclear
0% 20% 40% 60% 80% 100%
Patient selection
Index test
Reference standard
low high unclear
Risk of bias Applicability concerns
Fig. 2 QUADAS-2 findings on the qualitative assessment of the studies selected
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artifact in the bladder and kidney for 68Ga-PSMA-11 [24].
According to Heußer et al. [22], the halo artifact can also be
reduced by lowering the maximum scatter fraction rate.
The choice of particular MRI sequences has an important
influence on the detection of local and distant metastases, as
suggested by Metser et al. [53].
The correlation between the apparent diffusion coefficient
(ADC) and the standardized uptake value (SUV) is controver-
sial. Wetter et al. [9] found an inverse correlation between
ADC and SUV in bone metastases. Uslu-Besli et al. [49]
and Tseng et al. [43] likewise reported an inverse correlation
between the maximum SUV and the metabolic tumor volume,
between uptake volume product and the ADC in primary tu-
mor, respectively. Wetter et al. [12], on the other hand, found
no correlation between ADC and SUV in primary cancer.
Quantitative results
A meta-analysis was performed on 23 studies (Fig. 1), 11
concerning the staging phase [16, 18, 27, 35, 38, 40, 44–47,
52], and 12 the restaging phase [8, 21, 23, 25, 26, 30, 32, 39,
42, 51, 56, 59]. Pooled sensitivities and specificities were
obtained for the former (staging), and a pooled detection rate
was computed for the latter (restaging).
Table 4 shows the pooled sensitivities and specificities for
primary PCa and lymph node disease, showing a higher
pooled sensitivity for primary lesions in the patient-based
analysis (94.9% [95% CI 87.5–98.6]) than in the lesion-
based analysis (61.5% [95% CI 40.6–79.8]). Vice versa, the
pooled specificity was higher in the lesion-based analysis than
in the patient-based analysis (90.9% [95% CI 80–97] vs.
62.5% [95% CI 43.7–78.9], respectively). For lymph node
disease, the pooled sensitivity and specificity were similar in
the two types of analysis. The heterogeneity between the stud-
ies ranged between 0 and 98.3%.
At restaging, the pooled detection rate was 80.9% (95% CI
73.0–86.9%) (Table 5). The pooled detection rate was higher
for studies using PET/MRI with radiolabeled PSMA than for
those with radiolabeled choline (81.8 vs. 77.3%). The hetero-
geneity between the studies was high (> 80%). There was also
evidence of publication bias, as illustrated by the funnel plot
(Supplemental Figure 1).
In the studies that compared PET/CT with PET/MRI in the
same population, the pooled detection rates were 95.4% (95%
CI 87.0–98.5) and 93.9% (95% CI 85.4–97.6), respectively;
and, here again, the heterogeneity among the studies was >
80%.
Discussion and conclusions
The data emerging from the available literature suggest some
considerations.
Table 2 Detection rates of PET/MRI in restaging
Authors Ref N of pts Detection rate
Afshar-Oromieh et al. [59] 20 80%
Freitag et al. [30] 119 78.2%
Lütje et al. [25] 25 89.6%
Hope et al. [26] 150 82%
PSA level:
58% (< 0.2 ng/mL)
64% (0.2–0.5 ng/mL)
64% (0.5–1 ng/mL)
67% (1–1.5 ng/mL)
100% (1.5–2 ng/mL)
93% (2–5 ng/mL)
93% (> 5 ng/mL)
PSAdt:
83% (0–3 months)
90% (3–6 months)
97% (6–12 months)
88% (> 12 months)
Eiber et al. [21] 75 84.7% (team readers 1)
85.3% (team readers 2)
Lake et al. [23] 55 89.1%
PSA level:
75% (0–1 ng/mL)
80% (1–2 ng/mL)
94.6% (≥2 ng/mL)
Kranzbühler et al. [32] 56 78.6%
PSA level:
44.4% (< 0.2 ng/mL)
72.7% (0.2–< 0.5 ng/mL)
80% (0.5–< 2 ng/mL)
95.2% (≥ 2 ng/mL)
Grubmüller et al.* [34] 117 85.5%
PSA level:
65% (0.2 to < 0.5 ng/mL)
85.7% (0.5–< 1 ng/mL)
85.7% (1–< 2 ng/mL)
100% (≥ 2 ng/mL)
Riola-Parada et al. [39] 27 55.56%
PSA level:
42.86% (< 1 ng/mL)
0% (1–1.9 ng/mL)
75% (2–2.9 ng/mL)
71.43% (3–3.9 ng/mL)
60% (≥ 4 ng/mL)
Ferda et al. [42] 100 94%
PSA level:
33.3% (< 0.2 ng/mL)
88.89% (0.2–2 ng/mL)
97.96% (2.1–5 ng/mL)
100% (5.1–10 ng/mL)
100% (≥10.1 ng/mL)
Achard et al. [51] 58 58.6%
PSA level:
12.5% (< 0.5 ng/mL)
42.9% (0.5–1 ng/mL)
60% (1–2 ng/mL)
85.7% (≥ 2 ng/mL)
Abufaraj et al. [8] 65 97%
Kranzbuhler et al. [56] 66 54.5%
PSA level:
38.5% (< 0.2 ng/mL)
65% (0.2–0.5 ng/mL)
PSA, prostate-specific antigen; dt, doubling time
* Both PET/MRI and PET/CT
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1). The ability of PET/MRI with radiolabeled PSMA to de-
tect dominant lesions (pooled sensitivity for sextant-
based analysis, 80%) may suggest a further search on
prostate fusion biopsy of the suspected area. A recent
paper by Westphalen et al. [62] reported a low positive
predictive value (PPV) of PI-RADS for identifying pri-
mary PCa. After reviewing mpMRI images from 3449
patients for a total of 5082 lesions, the authors found a
PPV of 5% for PI-RADS 2, 15% for PI-RADS 3, 39%
for PI-RADS 4, and 72% for PI-RADS 5. Park et al. [38]
found that PET/MRI with 68Ga-PSMA-11 had a higher
PPV than mpMRI for bilateral tumors (70 vs. 18%, re-
spectively). Two articles discussed about the role of PET/
MRI for the diagnosis of PCa. Taneja et al. [37] and Jena
et al. [44] showed that dual-phase simultaneous 68Ga-
PSMA-11 PET/MRI is able to characterize prostate le-
sions, in 117 patients. In particular, Taneja et al. reported
that malignant lesions have higher PSMAuptake than the
benign ones, mainly in the delayed images (acquired af-
ter about 50 min form tracer injection) due to a possible
Table 3 Detection rates for
radiolabeled PSMA and Choline
PET/CT vs. PET/MRI in Prostate
Cancer
N Authors Ref Type of analysis Detection rate PET/
CT
Detection rate PET/
MRI
1 Afshar-Oromieh
et al.
[59] Lesion-based 74/75 (99%) 69/75 (92%)
2 Souvatzoglout et al. [10] Lesion-based 79/80 (99%)
LR: 19
LN: 42
DM: 18
77/80 (96%)
LR: 20
LN: 40
DM: 17
3 Freitag et al. [16] Patient-based LR: 9/119 (8%) 18/119 (16%)
4 Domachevsky et al. [20] Lesion-based 63/63 (100%) 61/63 (97%)
5 Eiber et al. [21] Patient-based
Lesion-based
(R-1)
Lesion-based
(R-2)
58/75 (77%)
155/188 (82%)
LR: 24
LN: 74
DM: 57
160/188 (85%)
LR: 36
LN: 72
DM: 62
63/75 (84%)
148/188 (79%)
LR: 36
LN: 60
DM: 52
143/188 (76%)
LR: 32
LN: 60
DM: 51
6 Lutje et al. [25] Lesion-based 36/46 (78%)
LR: 9
LN: 20
DM: 7
43/46 (93%)
LR: 14
LN: 23
DM: 6
7 Freitag et al. [30] Lesion-based 89/90 (99%) 90/90 (100%)
LR local recurrence, LN lymph node, DM distant metastasis; R reader
Table 4 Pooled sensitivity and specificity for staging
Site of disease (type of
analysis)
Pooled sensitivity
(95% CI)
Heterogeneity (P
value)
I-square
(%)
Pooled specificity
(95% CI)
Heterogeneity (P
value)
I-square
(%)
Primary tumor (per-lesion) 61.5% (40.6–79.8) 0.39 (0.531) 0 90.9% (80–97) 8.05 (0.005) 87.6
Primary tumor (per-patient) 94.9% (87.5–98.6) 3.14 (0.076) 68.2 62.5% (43.7–78.9) 0.32 (0.571) 0
Primary tumor (sextant-based) 79.3% (76–82.3) 68.28 (< 0.005) 98.3 83.4% (80.2–86.3) 27.16 (< 0.005) 96.3
Lymph node metastases
(per-lesion)
64.3% (44.1–81.4) 2.85 (0.091) 64.9 97.4% (91–99.7) 3.91 (0.048) 74.4
Lymph node metastases
(per-patient)
66.7% (49.8–80.9) 0.58 (0.748) 0 93.4% (87.5–97.1) 37.12 (< 0.005) 94.6
CI confidence interval
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role of receptor density and longer retention of PSMA in
PCa over time. Moreover, Jena et al. [44] concluded that
combining PET data, MRI data, PSA levels, and digital
rectal examination resulted in a better characterization of
prostatic lesions, with an AUC of 0.94 ± 0.29. However,
in the setting of primary PCa, MRI-TRUS fusion biopsy
using mpMRI will remain the standard for prostate can-
cer probably for longer time due to a very high-quality
study [63]. Similar studies for PSMA PET/MRI-guided
biopsy are needed to compete with mpMRI in order to
elucidate the advantages in terms of diagnostic efficiency
and costs.
Although the detection of more lesions by use of PET/
MRI in primary setting may not necessarily lead to better
outcome in general, the identification of oligometastasic
disease would be useful for guiding to an appropriate
treatment management (extension of the radiation field,
extension of lymph node adenectomy, etc.) therefore
allowing a long-term prognosis of the patients.
2). Targeted therapies could be directed by PET/MRI with
radiolabeled PSMA because of its ability both to detect
the most aggressive lesion and to assess the extracapsular
extension of disease. This latter information would be
useful not only to guide to more precise surgical ap-
proach, but it can be useful for focal or less-invasive
treatments.
3). PET/MRI with radiolabeled PSMA could be used for
early disease recurrences (PSA levels < 0.5 ng/mL) be-
cause it can raise the detection rate to 65% and could also
be helpful in guiding MDT. It seems that mpMRI can
suffice for identifying PCa recurrences in the prostatic
fossa. However, the added value of PET/MRI is its abil-
ity to detect also the lymph node involvement thus guid-
ing to a specific salvage therapy, especially in case of
radiotherapy. Furthermore, in case of a positivity only
in the lymph node, a salvage lymph node dissection
can be planned, by evaluating also the possible nerve or
other neighboring structure involvement.
4). PSMA PET/MRI is more detectable than choline PET/
MRI in staging and in restaging, although head to head
comparative data are missing.
5). PSMA PET/MRI can prompt changes to the manage-
ment of PCa patients in up to 75% of cases at restaging.
It means that in population of 100 patients with a PCa,
the inclusion of PET/MRI in the diagnostic algorithm has
a deep effect on the management and therefore on the
short- and long-term prognosis. However, more data are
necessary for this latter indication, being the literature
scarce.
This hybrid imaging modality has some limitations, how-
ever, such as the need for scatter correction and long acquisi-
tion times. The accurate description and interpretation of the
results are also key challenges for radiologists/specialists in
nuclear medicine and urologists alike.
In short, PET/MRI seems to have potential applications in
the following: (1) the diagnosis of primary tumor; (2) facili-
tating biopsy targeting; (3) predicting or monitoring tumor
aggressiveness (especially during active surveillance); (4)
the early detection of recurrent PCa; and (5) guiding targeted
therapies.
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